Results 321 to 330 of about 260,498 (362)

HIV-1 protease inhibitors.

AIDS clinical review, 1997
Objective. —The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of HIV-specific protease inhibitors (Pis). The 4 Pls available are saquinavir mesylate, ritonavir, indinavir sulfate, and nelfinavir mesylate.
S G, Deeks, P A, Volberding
openaire   +3 more sources

Inhibitors of HIV-1 Protease

Journal of Enzyme Inhibition, 1992
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion.
openaire   +2 more sources

Hyperlipidemia and inhibitors of HIV protease

Current Opinion in Clinical Nutrition and Metabolic Care, 2001
HIV protease inhibitors have been successfully incorporated into therapy for patients with HIV. These otherwise efficacious treatments present with multiple metabolic side-effects and body habitus changes known as the lipodystrophy syndrome. Direct associations of the lipid abnormalities with protease inhibitor use have been described, and ongoing ...
O, Distler, D A, Cooper, R J, Deckelbaum, S L, Sturley   +3 more
openaire   +2 more sources

Brain Delivery of HIV Protease Inhibitors

Archiv der Pharmazie, 2003
AbstractTo overcome the problems of peptidomimetic drug delivery to the specific organs, the use of dihydropyridine ↔ pyridinium chemical delivery systems to deliver peptides to the brain is considered in this work. An HIV protease inhibitor lead compound; KNI 279 was selected for the study.
Mahmoud M, Sheha, Nawal A, el-Koussi, Hassan H, Farag   +2 more
openaire   +2 more sources

Heterocyclic HIV-1 Protease Inhibitors

Organic Letters, 1999
[formula: see text] A series of simple heterocyclic HIV-1 protease inhibitors were developed on the basis of size, shape, and electronic complementarity to the active site of the enzyme. The C2-symmetric heterocycles do not contain a transition-state isostere nor are they active site directed irreversible inhibitors; thus, they represent the success of
openaire   +2 more sources

Perspectives in HIV Protease Inhibitors

1996
The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV.
openaire   +2 more sources

Screening efficacy of available HIV protease inhibitors on COVID-19 protease

, 2020
M. Mirzaei, K. Harismah, M. Da'i, E. Salarrezaei, Zahra Roshandel   +4 more
semanticscholar   +1 more source

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

AIDS (London), 1998
A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, D. Chisholm, D. Cooper   +6 more
semanticscholar   +1 more source

A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors

Annals of Internal Medicine, 2001
Honghu Liu, C. Golin, L. Miller, R. Hays, C. Beck, Sam Sanandaji, Judith Christian, Tomasa Maldonado, Dena Duran, A. Kaplan, N. Wenger   +10 more
semanticscholar   +1 more source

Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.

Science, 1994
PatrickY.-S. Lam, P. Jadhav, C. Eyermann, C. Hodge, Y. Ru, L. Bacheler, J. Meek, M. Otto, M. Rayner, Yn Wong   +9 more
semanticscholar   +1 more source